Alap Choudhari
Teva Pharmaceuticals, USA
Title: Recent developments in Abuse-deterrent and tamper-resistant opioid formulations and its changing regulatory requirements
Biography
Biography: Alap Choudhari
Abstract
During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic and acute pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescription opioid-related harm is a complex, multifactorial issue that requires a multifaceted solution. To confront the staggering human and economic toll created by opioid abuse and addiction, employing novel technologies are one part of a comprehensive intervention strategy that can deter abuse of prescription opioid analgesics without creating barriers to the safe use of prescription opioids. Abuse-resistant opioids include those that use some kind of physical barrier to prevent tampering with the formulation. Abuse-deterrent opioids are not necessarily resistant to tampering but contain substances that are designed to make the formulation less attractive to abusers. Some significant technological advances are made by researchers and institutions to develop the formulation which can achieve the tamperproof formulation while maintaining the desired pharmacokinetic profile for the opioids.